摘要
目的观察白芍总苷(TGP)联合柳氮磺吡啶(SASP)和甲氨蝶呤(MTX)治疗强直性脊柱炎的临床疗效和安全性。方法将72例强直性脊柱炎患者随机分为对照组和观察组,每组36例。对照组口服甲氨蝶呤和柳氮磺吡啶治疗,观察组在对照组基础上,加服白芍总苷,连续治疗3个月,观察3个月后2组患者的临床指标改善和不良反应发生情况。结果治疗后,2组胸廓扩张度较治疗前增大,晨僵持续时间较治疗前减短,Schober试验、C反应蛋白和红细胞沉降率优于治疗前(P<0.05或P<0.01);观察组各指标改善情况均优于对照组(P<0.05或P<0.01)。观察组不良反应发生率为8.33%,低于对照组的27.78%(P<0.05)。结论白芍总苷联合甲氨蝶呤和柳氮磺吡啶治疗强直性脊柱炎具有良好的疗效,且安全性高。
Objective To observe the clinical efficacy and safety in treatment of ankylosing spondylitis by taking total glucosides of paeony （TGP） combined with sulfasalazine （SASP） and methotrexate （MTX）. Methods 72 cases of ankylo- sing spondylitis were randomly divided into two groups control group and treatment group with each group of 36 cases. The control group were treated with methotrexate and sulfasalazine and treatment group were treated with additional total glucosides of paeony except the medicine taken by the control group, continuous treatment for 3 months, compared to 3 months after the two groups of patients with clinical indexes and adverse reactions. Results After treatment, for the 2 groups, thoracic dilatation in- creased and the duration of morning stiffness was shorter compared with that before treatment, and the Schober test, C-reactive protein and erythrocyte sedimentation rate were better than those before treatment （P 〈 0.05 or P 〈 0.01 ）. The improvement of each group was better than that of the control group （ P 〈 0.05 or P 〈 0.01 ）. The incidence of adverse reactions in the observa- tion group was 8.33 %, which was lower than that of the control group 27.78 % （P 〈 0.05 ）. Conclusion The total glucosides combined with methotrexate and sulfasalazine in treatment of ankylosing spondylitis has good curative effect and high level of security.
出处
《临床合理用药杂志》
2017年第8期9-10,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
白芍总苷
甲氨蝶呤
柳氮磺吡啶
强直性脊柱炎
Total glucosides of paeony
Methotrexate
Sulfasalazine
Ankylosing spondylitis
